PCSK9 and coronary artery disorder: PCSK9 inhibitors, such as evolocumab and alirocumab, were subsequently approved (Shapiro et al., 2018), and have demonstrated consistent efficacy in clinical trials for the lowering of LDL-cholesterol and prevention of CAD (Karatasakis et al., 2017; Shapiro et al., 2018).